SAB Biotherapeutics (SABS) to Release Earnings on Monday

SAB Biotherapeutics (NASDAQ:SABS) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 19th. Analysts expect the company to announce earnings of ($1.00) per share and revenue of $0.13 million for the quarter.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Friday, May 9th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.44. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. On average, analysts expect SAB Biotherapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SAB Biotherapeutics Stock Down 4.6%

SABS opened at $1.85 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.01. The firm’s fifty day moving average is $1.52 and its 200 day moving average is $2.52. The stock has a market cap of $17.19 million, a price-to-earnings ratio of -0.50 and a beta of 0.47.

Wall Street Analyst Weigh In

Several research firms have commented on SABS. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of SAB Biotherapeutics in a report on Thursday. HC Wainwright began coverage on shares of SAB Biotherapeutics in a report on Wednesday. They set a “buy” rating and a $10.00 price objective for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $12.20.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.